Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study

H. Müllerová; D. K. Finch; A. Agustí; M. Alacqua; G. P. Anderson; R. Beasley; L. Belton; A. De Giorgio-Miller; J. M. Fitzgerald; R. Hughes; I. D. Pavord; D. Price; E. Rapsomaniki; M. Sadatsafavi; J. Vestbo; E. H. Bel

Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study

H. Müllerová^* (Corresponding Author), D. K. Finch, A. Agustí, M. Alacqua, G. P. Anderson, R. Beasley, L. Belton, A. De Giorgio-Miller, J. M. Fitzgerald, R. Hughes, I. D. Pavord, D. Price, E. Rapsomaniki, M. Sadatsafavi, J. Vestbo, E. H. Bel

^*Corresponding author for this work

Research output: Contribution to conference › Abstract › peer-review

Abstract

Background: Blood eosinophil count (bEOS) is an important biomarker in obstructive lung disease. NOVELTY (NCT02760329) is a global, prospective, observational study with potential to identify obstructive lung disease phenotypes associated with differential outcomes, using biomarkers and clinical features. Objective: To evaluate factors associated with bEOS in patients with either physician-assigned asthma or COPD in NOVELTY.

Original language	English
Publication status	Accepted/In press - 27 Jul 2020
Event	30th ERS International Congress - Virtual Event Duration: 7 Sept 2020 → 9 Sept 2020

Conference

Conference	30th ERS International Congress
Period	7/09/20 → 9/09/20

Cite this

Müllerová, H., Finch, D. K., Agustí, A., Alacqua, M., Anderson, G. P., Beasley, R., Belton, L., De Giorgio-Miller, A., Fitzgerald, J. M., Hughes, R., Pavord, I. D., Price, D., Rapsomaniki, E., Sadatsafavi, M., Vestbo, J., & Bel, E. H. (Accepted/In press). Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study . Abstract from 30th ERS International Congress.

Müllerová, H, Finch, DK, Agustí, A, Alacqua, M, Anderson, GP, Beasley, R, Belton, L, De Giorgio-Miller, A, Fitzgerald, JM, Hughes, R, Pavord, ID, Price, D, Rapsomaniki, E, Sadatsafavi, M, Vestbo, J & Bel, EH 2020, 'Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study ', 30th ERS International Congress, 7/09/20 - 9/09/20.

@conference{2786db04f1d949b39356d53e4eb16cf6,

title = "Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study ",

abstract = "Background: Blood eosinophil count (bEOS) is an important biomarker in obstructive lung disease. NOVELTY (NCT02760329) is a global, prospective, observational study with potential to identify obstructive lung disease phenotypes associated with differential outcomes, using biomarkers and clinical features. Objective: To evaluate factors associated with bEOS in patients with either physician-assigned asthma or COPD in NOVELTY. ",

author = "H. M{\"u}llerov{\'a} and Finch, {D. K.} and A. Agust{\'i} and M. Alacqua and Anderson, {G. P.} and R. Beasley and L. Belton and {De Giorgio-Miller}, A. and Fitzgerald, {J. M.} and R. Hughes and Pavord, {I. D.} and D. Price and E. Rapsomaniki and M. Sadatsafavi and J. Vestbo and Bel, {E. H.}",

year = "2020",

month = jul,

day = "27",

language = "English",

note = "30th ERS International Congress ; Conference date: 07-09-2020 Through 09-09-2020",

}

TY - CONF

T1 - Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD

T2 - 30th ERS International Congress

AU - Müllerová, H.

AU - Finch, D. K.

AU - Agustí, A.

AU - Alacqua, M.

AU - Anderson, G. P.

AU - Beasley, R.

AU - Belton, L.

AU - De Giorgio-Miller, A.

AU - Fitzgerald, J. M.

AU - Hughes, R.

AU - Pavord, I. D.

AU - Price, D.

AU - Rapsomaniki, E.

AU - Sadatsafavi, M.

AU - Vestbo, J.

AU - Bel, E. H.

PY - 2020/7/27

Y1 - 2020/7/27

N2 - Background: Blood eosinophil count (bEOS) is an important biomarker in obstructive lung disease. NOVELTY (NCT02760329) is a global, prospective, observational study with potential to identify obstructive lung disease phenotypes associated with differential outcomes, using biomarkers and clinical features. Objective: To evaluate factors associated with bEOS in patients with either physician-assigned asthma or COPD in NOVELTY.

AB - Background: Blood eosinophil count (bEOS) is an important biomarker in obstructive lung disease. NOVELTY (NCT02760329) is a global, prospective, observational study with potential to identify obstructive lung disease phenotypes associated with differential outcomes, using biomarkers and clinical features. Objective: To evaluate factors associated with bEOS in patients with either physician-assigned asthma or COPD in NOVELTY.

M3 - Abstract

Y2 - 7 September 2020 through 9 September 2020

ER -

Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study

Abstract

Conference

Fingerprint

Cite this